Abstract Details

Title Comparison of Hospitalization Related to Multiple Sclerosis in Pre and Post Disease Modifying Therapy Eras

Topic MS and Related Diseases

Presentation(s) P03 - (-)

Poster/Presentation
Number 203

Objective

Background BACKGROUND: Multiple sclerosis is a chronic neurological disorder that leads to long term disability. It places a large burden on the health system through loss of productivity, recurrent hospitalization and related costs. Another major cost is that of DMT. These drugs have been shown in trials to reduce relapses and delay disability. Whether they reduce hospitalizations and related costs has not been well studied.

Design/Methods DESIGN/METHODS: The NIS database from 1990-1992 and 2008-2010 was searched for hospital discharges using ICD-9 admission code of 340(MS). We examined basic demographics and outcome measures including total discharges, hospital charges, length of stay and the national bill (total discharges multiplied by average hospital charge). MS prevalence was estimated utilizing various sources(NHIS, NMSS, other epidemiological studies).

Results RESULTS: The total discharges with a primary diagnosis of MS in 1990-92 were 64,285 compared to 71,280 in 2008-10 (p=0.024). Utilizing estimated prevalence ranges of MS in the USA - rates of hospitalization were 78.6 ± 8.6/1000 MS patients/yr for 1990-92 compared to 63.6 ± 4.8/1000 MS patients/yr for 2008-10 (p=0.004) . The total charges adjusted for inflation were $17,208 in 1990-92 versus $26,002 in 2008-10 (p<0.001). Length of stay decreased from 8.62 (1990-92) to 4.55 (2008-10). However, a larger proportion of discharges in 2008-10, were transfers to other facilities (23.4% vs 13.8%, p<0.001) as compared to 1990-92. The national bill adjusted for inflation and MS prevalence was $1352± 173/patient/yr for 1990-92 vs $1706± 160/patient/yr for 2008-10 (p=0.17).

Conclusions CONCLUSIONS: Hospitalizations due to MS decreased in the post-DMT era when accounting for the change in prevalence of MS. Costs related to hospitalization did not change significantly in the post-DMT era after adjusting for inflation and change in prevalence.

Authors/Disclosures
Pavan Bhargava, MD, FAAN (Johns Hopkins University) PRESENTER	The institution of Dr. Bhargava has received research support from EMD Serono. The institution of Dr. Bhargava has received research support from Amylyx pharmaceuticals. The institution of Dr. Bhargava has received research support from Genentech. The institution of Dr. Bhargava has received research support from GSK.
	No disclosure on file
Sushant P. Kale, MD	No disclosure on file
Gavin Giovannoni, MD (QMUL)	Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck KGaA. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche-Genentech. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Giovannoni has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Astoria Biologica. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zenas. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Giovannoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Giovannoni has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape.

��ɫ��

��ɫ��